A multi-center, open-label, single-Arm, phase 1, dose escalation study of ASONEP (sonepcizumab/LT1009) administered as a single agent weekly to subjects with refractory advanced solid tumors

Trial Profile

A multi-center, open-label, single-Arm, phase 1, dose escalation study of ASONEP (sonepcizumab/LT1009) administered as a single agent weekly to subjects with refractory advanced solid tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2014

At a glance

  • Drugs Sonepcizumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Lpath
  • Most Recent Events

    • 30 Mar 2010 Status changed from active, no longer recruiting to completed, as reported in an Lpath media release.
    • 09 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 13 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top